Rhythm Pharmaceuticals, a clinical-stage biotech developing injectable therapies for gastrointestinal diseases, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.
The Boston, MA-based company, which was founded in 2008, plans to list on the NASDAQ under the symbol RYTM. Rhythm Pharmaceuticals initially filed confidentially on July 15, 2014. Citi and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
